文献速递传染病防控与疫情报告卫生政策与健康促进

治疗性恰加斯病疫苗的经济价值:不确定期与心肌病患者

Economic value of a therapeutic Chagas vaccine for indeterminate and Chagasic cardiomyopathy patients.
PubMed 文献 · Vaccine · 2019-05-16

研究使用计算性恰加斯病Markov模型,评估治疗性疫苗联合苯并硝唑用于不确定期和慢性恰加斯病患者的临床与经济价值。结果表明,当疫苗降低疾病进展风险≥5%时,治疗性疫苗接种具有成本节约优势,且即使仅减少药物疗程和不良事件,在成本低于200美元时仍具成本效果。

要点

  • 治疗性疫苗联合苯并硝唑可提高治疗完成率并减少疾病进展、死亡和DALYs。
  • 疫苗降低进展风险≥5%时具有成本节约优势,即使仅减少药物疗程和不良事件,成本<200美元时仍具成本效果。
  • 在Kuschnir 1级和2级心肌病患者中,疫苗接种同样可减少进展、死亡和DALYs并节约成本。

核心结论

  • 治疗性恰加斯病疫苗在降低疾病进展风险≥5%时具有成本节约优势,且当疫苗成本低于200美元时,即使仅减少药物疗程和不良事件也具成本效果。

研究设计与样本

  • 研究采用计算性恰加斯病Markov模型,评估治疗性疫苗联合苯并硝唑用于不确定期和慢性恰加斯病患者(包括Kuschnir 1级和2级心肌病患者)的临床与经济价值。

主要发现

  • 与单用苯并硝唑相比,治疗性疫苗联合苯并硝唑(标准剂量和疗程减少25-75%)可使37-111例(每1000例)完成治疗,预防11-219例进展、6-120例死亡和108-2229 DALYs(进展风险降低5-100%),每例节省≤16171美元。
  • 对Kuschnir 1级心肌病患者接种疫苗,与单用苯并硝唑相比,减少10-197例进一步进展,避免11-228例死亡和144-3037 DALYs(进展风险降低5-100%),每人节省≤34059美元。
  • 对Kuschnir 2级心肌病患者接种疫苗,与单用苯并硝唑相比,减少13-279例进展(单用苯并硝唑组279例进展),避免13-692例死亡和283-10785 DALYs(进展风险降低5-100%),每人节省≤89759美元。
  • 当疫苗降低进展风险≥5%时,治疗性疫苗接种具有优势(节约成本并带来健康获益),但仅减少药物疗程和不良事件时除外;当疫苗成本<200美元时仍具成本效果。

关键数值与推荐

  • 疫苗降低心脏进展风险<5%且苯并硝唑治疗剂量和疗程减少25%时可能具有成本效果;降低进展风险≥5%且剂量和疗程减少25%时具有成本节约优势。

临床怎么用

  • 治疗性恰加斯病疫苗的临床和经济价值取决于其降低疾病进展风险的程度以及减少苯并硝唑治疗剂量、疗程和不良事件的能力。
  • 在疫苗成本低于200美元时,即使仅减少药物疗程和不良事件,治疗性疫苗接种仍可能具有成本效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Therapeutic vaccines to prevent Chagas disease progression to cardiomyopathy are under development because the only available medications (benznidazole and nifurtimox) are limited by their efficacy, long treatment course, and side effects. Better understanding the potential clinical and economic value of such vaccines can help guide development and implementation. METHODS: We developed a computational Chagas Markov model to evaluate the clinical and economic value of a therapeutic vaccine given in conjunction with benznidazole in indeterminate and chronic Chagas patients. Scenarios explored the vaccine's impact on reducing drug treatment dosage, duration, and adverse events, and risk of disease progression. RESULTS: When administering standard-of-care benznidazole to 1000 indeterminate patients, 148 discontinued treatment and 219 progressed to chronic disease, resulting in 119 Chagas-related deaths and 2293 DALYs, costing $18.9 million in lifetime societal costs. Compared to benznidazole-only, therapeutic vaccination administered with benznidazole (25-75% reduction in standard dose and duration), resulted in 37-111 more patients (of 1000) completing treatment, preventing 11-219 patients from progressing, 6-120 deaths, and 108-2229 DALYs (5-100% progression risk reduction), saving ≤$16,171 per patient. When vaccinating determinate Kuschnir class 1 Chagas patients, 10-197 fewer patients further progressed compared to benznidazole-only, averting 11-228 deaths and 144-3037 DALYs (5-100% progression risk reduction), saving ≤$34,059 per person. When vaccinating Kuschnir class 2 patients, 13-279 fewer progressed (279 with benznidazole-only), averting 13-692 deaths and 283-10,785 DALYs (5-100% progression risk reduction), saving ≤$89,759. Therapeutic vaccination was dominant (saved costs and provided health benefits) with ≥ 5% progression risk reduction, except when only reducing drug treatment regimen and adverse events, but remained cost-effective when costing <$200. CONCLUSIONS: Our study helps outline the thresholds at which a therapeutic Chagas vaccine may be cost-effective (e.g., <5% reduction in preventing cardiac progression, 25% reduction in benznidazole treatment doses and duration) and cost-saving (e.g., ≥5% and 25%, respectively).

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Bartsch SM, Bottazzi ME, Asti L, et al. Economic value of a therapeutic Chagas vaccine for indeterminate and Chagasic cardiomyopathy patients. Vaccine. 2019. PMID: 31104883. doi:10.1016/j.vaccine.2019.05.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。